NCT05618821 is a Phase 2 clinical trial of Indocyanine Green Tracer in Gastric Cancer, sponsored by Fujian Medical University.

Who is sponsoring NCT05618821?

NCT05618821 is sponsored by Fujian Medical University.

What drugs are being tested in NCT05618821?

Interventions in NCT05618821: Indocyanine Green Tracer.

What condition does NCT05618821 study?

NCT05618821 studies Gastric Cancer.

Is NCT05618821 still recruiting?

NCT05618821 is currently recruiting now. Last updated 16 November 2022.

Last reviewed 2022-11-16 · How we verify

NCT05618821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer

Recruiting now Phase 2 Last updated 16 November 2022

What this trial tests

Phase 2 trial testing Indocyanine Green Tracer in Gastric Cancer in 68 participants. Currently enrolling.

Timeline

3 June 2022

Primary endpoint
1 April 2025

1 April 2028

Quick facts

Lead sponsor	Fujian Medical University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	3 June 2022
Primary completion	1 April 2025
Estimated completion	1 April 2028
Sites	1 location across China

Drugs / interventions tested

Indocyanine Green Tracer — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Fujian Medical University

Who can join

Adults 18 to 75, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with resectable remnant gastric cancer were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic lymph node dissection for remnant gastric cancer by comparing injection ICG group and non-injection ICG group.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Potential Probes for Targeted Intraoperative Fluorescence Imaging in Gastric Cancer.
Martinelli S, Fortuna L, Coratti F, Passagnoli F, et al · · 2024 · cited 4× · PMID 39766041 · DOI 10.3390/cancers16244141

Verify or expand the search:

Other trials of Indocyanine Green Tracer

Trials testing the same drug.

NCT03050879 — Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection · Phase 2 · completed

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Fujian Medical University trials

Trials by the same sponsor.

NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05618821 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
Last refreshed: 16 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05618821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing